Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone
- 30 November 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (11) , 1458-1461
- https://doi.org/10.1016/0277-5379(91)90031-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycleBritish Journal of Cancer, 1991
- Multihormonal Regulation of Insulin-Like Growth Factor-I-Related Protein in MCF-7 Human Breast Cancer CellsMolecular Endocrinology, 1988
- LHRH agonists and human breast cancer cellsNature, 1987
- Combined effects of Buserelin, estradiol and Tamoxifen on the growth of MCF-7 human breast cancer cells in vitroBiochemical and Biophysical Research Communications, 1986
- Treatment of Breast Cancer with Gonadotropin-Releasing HormoneEndocrine Reviews, 1986
- Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cellsEuropean Journal of Cancer and Clinical Oncology, 1985
- Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancerJournal of Steroid Biochemistry, 1985
- Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonistNature, 1985
- TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1982
- Reduction of LH-RH pituitary and estradiol uterine binding sites by a superactive analog of luteinizing hormone-releasing hormoneBiochemical and Biophysical Research Communications, 1980